FindTrial
Sign In

To compare the effects of injecting Intra- Articular Platelet-Rich Plasma and Hypertonic Dextrose Prolotherapy in Osteoarthritis Knee

The comparative effects of injecting Intra- Articular Platelet-Rich Plasma and Hypertonic Dextrose Prolotherapy in Osteoarthritis Knee- A Randomized Control Trial

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2021/06/034367
Enrollment
100
Registered
2021-06-24
Start date
Unknown
Completion date
Unknown
Last updated
2024-01-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: M15-M19- Osteoarthritis Health Condition 2: M179- Osteoarthritis of knee, unspecified

Interventions

Intervention1: Intra Articular Injection in Osteoarthritis Knee : Group A: Platelet Rich Plasma 5ml Group B: 25% Hypertonic Dextrose 5ml , One intra articular injection of 5ml in the affected knee on

Sponsors

King Georges Medical University
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: (1) Age =50 to (2) Diagnosis of primary knee OA based on clinical criteria as defined by the American college of Rheumatology Association. 3) Moderate to severe knee pain for at least 3 months. 4) Failure to achieve pain and swelling reduction after 3 months of usual care, such as weight reduction, exercise, physical therapy and pharmacological treatment. 5) Radiographic evidence of knee OA (KL grade 1, grade 2, grade3). 6) BMI 7) Patient willing to participate in the study.

Exclusion criteria

Exclusion criteria: 1) History with uncontrolled Diabetes Mellitus. 2) OA knee: KL grade 4. 3) Patients on anticoagulant therapy. 4) Prior intra-articular knee injections within 3 months, other than platelet- rich plasma therapy (PRP therapy) and hypertonic dextrose prolotherapy 5) Inflammatory or post-infectious knee arthritis, such as clinically diagnosed rheumatoid arthritis, gouty arthritis, psoriatic arthritis and septic arthritis. 6) A history of previous knee pathology. 7) A history of any recent trauma to the hip joint or in the pelvic region interfering with ADL or causing any deformity 8) Patients with Hb 9) Paralysis of lower extremities. 10) Significant effusion as defined by a ballotable patella. 11) Any disease other than osteoarthritis Knee

Design outcomes

Primary

MeasureTime frame
To compare the effects of Platelet-Rich Plasma and 25% Hypertonic Dextrose Prolotherapy in patients with Osteoarthritis Knee in terms of (1) Numeric Pain Rating Scale (2) Laquesne Knee Index (LKI)Timepoint: 6 weeks—

Secondary

MeasureTime frame
1) Reduction of pain, according to Numeric pain rating scale (NPRS) 2) Discomfort,walking and activities of daily living(ADL) according to Lequesne knee index (LKI) Timepoint: 0 week (immediately prior to first injection) 6 weeks after the first injection.—

Countries

India

Contacts

Public ContactDr Neeraj Singh

King George Medical University

dranilaiims@yahoo.co.in7839451035

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026